Axsome Therapeutics Added to NASDAQ Biotechnology Index – Yahoo Finance

Posted on by

NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has been selected for addition to the NASDAQ Biotechnology Index (^NBI), as part of the annual index evaluation. The Companys addition to the index will become effective prior to the market open on Monday, December 23, 2019.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). Companies in the NASDAQ Biotechnology Index must also meet certain other eligibility criteria, including minimum market capitalization, average daily trading volume, and seasoning as a public company. The index forms the basis for a number of Exchange Traded Funds (ETFs).

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsomes core CNS product candidate portfolio includes four clinical-stage candidates, AXS-05, AXS-07, AXS-09, and AXS-12. AXS-05 is currently in a Phase 3 trial in treatment resistant depression (TRD), a Phase 2/3 trial in agitation associated with Alzheimers disease (AD), and is being developed for major depressive disorder (MDD). AXS-05 is also being developed for smoking cessation treatment. AXS-07 is currently in two Phase 3 trials for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-05, AXS-07, AXS-09, and AXS-12 are investigational drug products not approved by the FDA. For more information, please visit the Companys website at axsome.com. The Company may occasionally disseminate material, nonpublic information on the company website.

Forward Looking Statements

Certain matters discussed in this press release are forward-looking statements. We may, in some cases, use terms such as predicts, believes, potential, continue, estimates, anticipates, expects, plans, intends, may, could, might, will, should or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Companys statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application (NDA) for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration (FDA) or other regulatory authority approval of, or other action with respect to, our product candidates (including, but not limited to, FDAs agreement with the Companys plan to discontinue the bupropion treatment arm of the ADVANCE-1 study in accordance with the independent data monitoring committees recommendations); the potential for the ASCEND clinical trial, combined with the GEMINI clinical trial results, to provide a basis for approval of AXS-05 for the treatment of major depressive disorder and accelerate its development timeline and commercial path to patients; the Companys ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Companys research and development programs and collaborations; the success of the Companys license agreements; the acceptance by the market of the Companys product candidates, if approved; the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings prior to the readout from its Phase 3 trials; and other factors, including general economic conditions and regulatory developments, not within the Companys control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

Story continues

Axsome Contact: Mark JacobsonSenior Vice President, OperationsAxsome Therapeutics, Inc.200 Broadway, 3rd FloorNew York, NY 10038Tel: 212-332-3243Email:mjacobson@axsome.comwww.axsome.com

Original post:
Axsome Therapeutics Added to NASDAQ Biotechnology Index - Yahoo Finance

Investigating the World of Biotechnology Management and Entrepreneurship – Yu News

Posted on by

According to Dr. Rana Khan, the MS in Biotechnology Management and Entrepreneurship (BME) at the Katz School of Science and Health is one of a handful of national biotechnology graduate programs that are interdisciplinary in nature and focused on entrepreneurship. Dr. Khan, the founding director of the program, noted that what makes the program stand out is that our students learn by doing and are exposed to various aspects of biotechnology industry via case studies, guest speakers and hands-on projects.

On Monday, Dec. 16, 2019, five students presented their capstone projects, becoming the first cohort of students to complete the requirements for the masters degree. Robert Friedman 78YC, the professor in the biotechnology management course for which the students were doing their presentations, noted that purpose of the capstone is for the students to integrate as much as possible from what they have learned at BME.

Each capstone project is structured around a selected company. The student, using information culled from a multitude of sources, creates, in essence, a business plan for the company that examines such areas as the companys product, potential competitors and allies, possible markets and advertising plans for accessing those markets, to name just a few of the areas covered by the project. The goal is to create a plan that will help the company increase its market presence, improve its performance and make it more attractive to potential investors.

The five students were given their final assignments based on projects solicited from companies and assigned them based on the fit as determined by the course professor and the programs director. Creation of the presentation started essentially on the first day of class, said Friedman. The class met at regular intervals and provided updates on their research projects in PowerPoint presentation format. In essence, they were creating the final document at every step of the research process.

To make the project even closer to real life, students and faculty signed non-disclosure agreements prior to commencing work. As in most strategic consulting processes, Friedman explained, the company maintains intellectual property rights to the work produced, except to the elements of the report that were not confidential and were sourced from publicly available information.

Here are the five presentations:

Alana ReichenbergLibra@Home uses portable virtual reality technologies to present physical therapy exercises to motivate patients to take an active role in their therapy. The company is based in Jerusalem. Alana researched the physical therapy equipment market to identify the key players, understand their business model and define the value proposition that Libra@Home system requires to be a fit for these distributors to commercialize the product.

Josh LankinSFA Therapeutics is a development-stage bio-pharmaceutical startup company. Josh developed a business plan focusing on SFA Therapeutics core business of developing microbiome-derived drugs to treat chronic inflammatory diseases.

Devorah LammFor MatterBio, Devorah studied the current and future competitive landscape of gene therapy in cancer, outlined and compiled the intellectual property connected to certain key technologies and translated her research into an investor-ready vision for fund-raising.

Surosri Banerje and David WallachBoth students developed plans for ChalkSense, a data-driven and customer-centric management consulting service whose motto is making sense from the data dust. Surosi developed an analysis and preliminary strategy for an exploratory stage endeavor in the drug-device combination space for insulin pump improvements. David put together an integrated business strategy for EndpointGenie, an artificial intelligence assistant tool that enables strategic endpoint design and execution.

YU News had the pleasure of sitting in on the presentation done by Alana Reichenberg for Libra@Home, who had the honor of being the first out of the gate.

Connected to her contacts in Israel, Dario Geiseninger (founder and CEO) and Lacey McBride (business development and clinical liaison), through a Zoom conference room, Reicheberg presented step-by-step her findings about how Libra@Home might access markets in the United States and the challenges to the company in doing so, including a review of potential competitors in the world of providing physical therapy services.

At the end of the presentation, Reichenberg was critiqued by Friedman, Dr. Khan and Dr. Maria Blekher, director of the Innovation Lab, who sat in on the meeting. They all agreed that the plan presented was solid, and they also offered other avenues to pursue for research, such as Dr. Blekhers suggestion of reaching out to early adapters of technology, who might be more open to Libra@Homes software approach than companies more invested in other kinds of equipment and approaches.

Relieved to have done well, Reichenberg was also buoyed by the way the capstone project had sharpened and expanded her skills, especially because she wants to find employment as a clinical trial coordinator. As an undergraduate at Stern College, I had a major in biology and a minor in business management, she noted. I wanted to find a path that incorporated both, which is exactly what the BME program has given me. I have learned so much from my professors, the guest speakers and my fellow classmates. I am proud to be part of the first cohort to complete this program because I know this is just the beginning.

This is precisely what Dr. Khan and Friedman hoped the capstones would do for the students. Working on a project like this, said Dr. Khan, gives students firsthand experience of the issues biotechnology businesses have to research/consider at different stages. It expands our students professional network and provides opportunities for employment/recommendation letters. Furthermore, said Friedman, students learn how to put together a presentation for investors and to communicate effectively, both orally and in writing, within a given time. This is also something that will go on their resumes. He added that on a personal level, it has been a most gratifying experience; in some ways, I have learned as much, if not more, from my students than they have learned from me!

Find more information on the program at go.yu.edu/katz/biotechnology-management

Read more:
Investigating the World of Biotechnology Management and Entrepreneurship - Yu News

Connecticut a major player in growing biotechnology sector – Danbury News Times

Posted on by

Photo: Contributed Photo / Hearst Connecticut Media

Sonics Executive Vice President Lauren Soloff, left, stands with CEC Co-Chairs Joe McGee and William Tong at the Sonics headquarters in Newtown, Conn., in August 2017.

Sonics Executive Vice President Lauren Soloff, left, stands with CEC Co-Chairs Joe McGee and William Tong at the Sonics headquarters in Newtown, Conn., in August 2017.

Connecticut a major player in growing biotechnology sector

The growing biotechnology corridor in the region and improved collaboration between government and manufacturing companies are among the major focuses of the state Commission on Economic Competitiveness, said the co-chairmen of the commission during a recent visit to a Newtown manufacturer.

Life sciences is an area that can really become a major part of Connecticuts growing economy, said Joe McGee, co-chairman of the commission and also the vice president of public policy and programs at Stamford-based Business Council of Fairfield County. Precision medicine and its potential is an economic driver in the state.

McGee, along with co-chairman and state Rep. William Tong, D-147, last week toured Sonics & Materials, a Newtown-based manufacturer of ultrasonic liquid processors, plastic assembly equipment and metal welding systems. Formed in 1969, Sonics has developed a line of advanced ultrasonic liquid processors for applications in DNA sequencing and nanoparticle dispersion.

Its just unbelievable that a company, sitting in Newtown, Connecticut, has a machine that is critical for the sequencing of DNA, McGee said. It just shows you the viability of the Connecticut manufacturing sector.

McGee and Tong said Connecticut is a major player in a burgeoning biotechnology corridor that stretches from New York City into the Nutmeg State. Companies such as Sonics, which employs 75 people, and larger players such as Mount Sinai in Stamford, Boehringer Ingelheim in Ridgefield and Jackson Laboratory in Farmington make Connecticut a force in the life sciences industry, they said.

Tong said the New York City Department of Economic Development recently met with the Connecticut Health Data Collaborative and announced it is investing money to have biotechnology firms migrate into Connecticut.

They need Connecticut and we need them, Tong said. Its a big component of Connecticuts economic future.

Tong said the growing field will help the state reach its lofty expectations associated with the CT 500 program, the goal of which is to create 500,000 private-sector jobs in the state in the next 25 years.

McGee said the biotechnology corridor has a broad reach and it has only recently been targeted as a major economic driver for the state. The Commission on Economic Competitiveness, or CEC, is performing an asset analysis of the industry.

Its one of those things thats been hiding in plain sight, McGee said. There are a lot of places here of significance.

The CEC was created by the state Legislature in 2015 and is made up of lawmakers and private sector leaders with the goal of strengthening and improving the states economic competitiveness.

Lauren Soloff, executive vice president at Sonics, said McGee and Tong talked at length with employees and had a lunch outside after the tour. Soloff, a Westport resident, said the co-chairmen discussed how companies such as Sonics can partner with community colleges and vocational schools to strengthen the curriculum for advanced manufacturing programs.

Its nice to shine a bright light on some of the positive things happening in Connecticut, she said. It was an extremely positive meeting. They are both realists, but optimistic. It was one of the more upbeat visits weve ever had.

cbosak@hearstmediact.com; 203-731-3338

See original here:
Connecticut a major player in growing biotechnology sector - Danbury News Times

Master of Science in Biotechnology – Drexel University …

Posted on by

Biotechnology is the use of living organisms, or products of living organisms, for human benefit, and it has had a tremendous impact on many aspects of modern life. Its effects, however, are perhaps most keenly felt within the food/agricultural and medical fields. Biotechnological processes are used in the production of specific foods and have allowed the genetic modification of food crops to be hardier and to have increased nutritional value. The health care sector likewise has benefited from biotechnology to produce medicines and vaccines that prevent or cure disease. Moreover, biotechnological theory and methodologies will be central to the realization of personalized medicine.

At Drexel University, we are proud to offer the Master of Science in Biotechnology (BIOT), an innovative, non-thesis graduate degree program that emphasizes hands-on training in state-of-the-art laboratory techniques used across the biotechnology and biomedical industries.

This program furnishes students with the necessary technical skills to successfully seek gainful employment in both biotechnology/pharmaceutical firms and academic laboratories. It does so by using a two-pronged approach that combines theory with hands-on instruction under the direct supervision of our diverse and accomplished research faculty. The program is appropriate for recent college graduates or experienced technicians wishing to bolster their methodological base.

The Master of Science in Biotechnology program is ideally suited for enhancing the scientific skill set of the following groups:

"The Biotechnology master's program provided me with an excellent opportunity to gain a diverse set of technical skills, including those in biochemistry, biophysics and molecular biology, while exploring multiple areas of biomedical research. In addition, the experienced principal investigators and accelerated course work strengthened the knowledge I had gained throughout undergrad. Overall, the programs productive and focused curriculum at both the bench and in the classroom left me well qualified for positions in both academia and industry. On the strength of the Biotechnology Master of Science program at Drexel University, I have successfully secured positions in local biotech/pharma, and now work in the Screening Group at Janssen R&D (Johnson & Johnson) as an associate scientist."Jeff Branson, Class of 2016

The program encompasses both classes and hands-on practica. It is the inclusion of practica that makes this program unique, stressing applied learning of key methodologies used throughout academia and industry and their practical use in addressing research questions in bioscience and biomedicine. This innovative combination of technical theory and application will provide graduates of this program with a knowledge base and a set of skills that will make them very competitive for laboratory jobs in the academic or industrial sectors or enhance their potential for advancement at their current place of employment.

Swetaben Patel and Aishwarya Subramanian have taken positions at GlaxoSmithKline.

Lina Maciunas is currently pursuing a PhD at Drexel and works in the Loll Laboratory.

Jeff Branson is currently working as an associate scientist at Janssen R&D (Johnson & Johnson) in the Screening Group.

Ayonika Mukherjee has an internship at GlaxoSmithKline.

More:
Master of Science in Biotechnology - Drexel University ...

Amicus Therapeutics: A Rare Find In Biotechnology – Seeking Alpha

Posted on by

Amicus Therapeutics (NASDAQ:FOLD) is a global biotherapeutics company focused on rare genetic devastating diseases. The company has advanced its precision medicine, Galafold (migalastat), in treating patients in Europe with Fabry disease (alpha galactosidase A deficiency), a rare X-linked genetic lysosomal disorder in which sphingolipids are not metabolized properly. Galafold, an orally administered drug, is the first medicine approved (EMA but not yet FDA) for treatment of Fabry disease. Other goals for 2017 include submitting a J-NDA (Japan) for migalastat, establishing a clinical plan for ATB200/AT2221 in Pompe disease, completion of phase 3 clinical trial in epidermolysis bullosa.

FOLD announced its regulatory plan with FDA for U.S. treatment with Galafold in advancing it's Fabry disease program including two phase 3 trials in late 2016. As previously mentioned, the EMA approved use of Galafold for treatment of Fabry disease. The company published data from its pivotal trial in the New England Journal of Medicine. A statistically significant benefit was conferred by Galafold in 50 patients with treatable mutant galactosidase alleles. However, a closer look at the trial endpoints reveals that the study failed to reach its primary endpoints including greater than 50% reduction in GL-3 inclusions per kidney, and if all 67 patients were included in the study (including mutant alleles that are not expected to benefit by Galafold). More studies are needed for FDA going forward. It could be well worth the company's investment, as the market for Fabry's disease is estimated to be in excess of $1.2 billion by 2024.

December 2016, FOLD announced positive early phase 1/2 data for Pompe disease, a rare genetic disorder leading to the buildup of glycogen in the body, particularly the muscles, which become impaired in function. The study showed a positive safety profile with no serious adverse events and generally showed musculatoprotection as shown by biomarkers of muscle damage. The study is divided into three cohorts: non-ambulatory ERT-switch, ERT-switch, and ERT-naive. Creatine kinase, alanine aminotransferase, and aspartate aminotransferase levels showed a trend towards improvement in half the patients and were stable in all. ATB200/AT2221 has a unique mechanism of treatment that uses ATB200, a recombinant functional alpha-glucosidase enzyme carrying mannose-6 phosphate moieties designed to increase uptake. AT2221 is a pharmacological chaperone co-treated to stabilize the compound. The company believes that its Pompe program (with market of $1.2 billion) will be a driver in its growth with 12% CAGR as a world's leading rare disease company. Key study readout dates include Q2 and Q3 2017.

SD-101 is currently in phase 3 studies as a topical for Epidermolysis Bullosa, and FOLD believes it will be the first-to-market therapy for the rare indication. The inherited disease is characterized by blistering of keratinized outer skin, wet skin (such as mouth), and internal organs. Serious complications include infection, pain, and even death. The company was granted FDA Breakthrough Therapy Designation in 2013 based on results from its phase 2a study, having demonstrated wound closure in all disease types. Strong Bio has previously written about the impacts of FDA Breakthrough Therapy Designation on biotechnology stocks, and if you are an investor and have not perused the article, now might be a good time, as it is a part of the investment plan for FOLD. Phase 3 top-line data for the 160 patient study in which 95% of the patients elected to continue the open-label extension is due Q3 2017. This statement could be the company's way of saying they find it likely it will have clinical benefit for patients. Since it has been observed that FDA breakthrough therapy status stocks get volatile late in stage 3, any sharp drops may indicate stock manipulation that interested investors might jump on with a small position. Strong Bio regards FOLD as a nice investment prospect for any unexplainable late Q2 early Q3 pullbacks. With significant market potential of $1 billion, severe symptoms, and 30,000 sufferers in the U.S. alone, its worth watching for that pullback. One competitor, RegeneRx (OTCQB:RGRX) has initiated phase 3 trials for RGX-137 (active ingredient thymosin beta 4 wound healing gel) in the condition as well.

Cash burn was $55 million in first quarter 2017. Cash on hand at end Q1 was $280 million. The current runway is expected to last through the second half of 2018. Seven analysts average about $12 per share for FOLD, which is currently trading at about $8, which may be a slight pullback from fair value. Strong Bio will look for dips in price below $6 for no a brainer initial position. If all three drugs get FDA approval, this stock could be off to the races. Strong Bio has learned a lesson from Amicus. Rare diseases may have surprisingly large markets!

Risk factors for FOLD could include dilution (which may be yet another entry opportunity). Risks also include FDA approval and/or regulatory delays for all three major indications. Clinical trial design will be key, because FDA wants a clear metric upon which to agree with FOLD to approve these rare disease therapies. Large scale GMP-compliant manufacturing for U.S. application will also be a significant but manageable obstacle. Because the company has a market cap over $1.1 billion dollars, SD-101 key readout will be very important in terms of valuation for FOLD stock. If approved by FDA, the stock could easily triple in value over the next year. With ATB200/AT2221 being regarded as a key driver in value by the company, 2017 is going to be a pivotal year for FOLD. With three candidates all on the verge of pivotal data, this is a must-watch!

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read this article:
Amicus Therapeutics: A Rare Find In Biotechnology - Seeking Alpha

Puma Biotechnology Inc (PBYI) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS – The Cerbat Gem

Posted on by

Normangee Star
Puma Biotechnology Inc (PBYI) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS
The Cerbat Gem
Puma Biotechnology logo Puma Biotechnology Inc (NYSE:PBYI) issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus ...
Puma Biotechnology (PBYI) Given Daily Media Impact Score of 0.33Stock Observer
Puma Biotechnology Inc - Receive News & Ratings DailyBBNS

all 7 news articles »

View original post here:
Puma Biotechnology Inc (PBYI) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - The Cerbat Gem

Are you ‘anti-science’ if you resist biotechnology on political or economic grounds? – Genetic Literacy Project

Posted on by

[Editors note: Tess Doezema is a doctoral student at the School for the Future of Innovation in Society at Arizona State University, where she researches biotechnology promise and politics.]

[S]cientists and others offer a picture of a Manichean world divided into those who are for scientific and technological progress and those who are against ita representation of the world that we have been seeing more and more of lately in reports of a war on science. But drawing this line is dangerous. The real problem here is the regulatory process itself, which forces dissent to take the narrow form of challenges to scientific data and methodology and ignores other questions about whats at stake.

Some might read the vast public preoccupation with a broad set of social, political, and economic issues as the contamination of science with politics. But I would suggest that this is actually a case of the reverse problem: seemingly endless conflict around the AquAdvantage salmon reflects the limitation of using narrow scientific terms to address questions of broad social, political, and economic significance.

Scientists often dismiss resistance to the AquAdvantage salmon and other biotechnologies as borne of scientific ignorance. But its a lot easier to understand peoples reluctance if you realize that the debate is about much broader questions than science alone can answer.

Read the original post:
Are you 'anti-science' if you resist biotechnology on political or economic grounds? - Genetic Literacy Project

SQI Diagnostics to Exhibit at the National Biotechnology Conference – Yahoo Finance

Posted on by

TORONTO, May 1, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, will be exhibiting at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference in San Diego, California.

"We are pleased to be a contributor to this very prestigious conference," said Andrew Morris, CEO of SQI Diagnostics. "This event brings together the world's leading experts and representatives from all sectors of pharma and biotechnology drug development and gives us the opportunity to share our novel multiplexing applications in drug development testing. Over the past year, we have made significant progress in our work with our pharma and biotech customers and believeour unique productswill prove to be beneficial to our customers who are large, global pharmaceutical companies.

The conference will run from May 1-3, 2017. Please stop by and visit us at booth 316.

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit http://www.sqidiagnostics.com.

Contacts:

Sales and Marketing Contact: Russ Peloquin Vice President, Global Commercial Operations 913.484.9022 rpeloquin@sqidiagnostics.com

Investor Relations Contact: Andrew Morris Chief Executive Officer 416.674.9500 ext. 229 amorris@sqidiagnostics.com

Forward-looking Information

This news release contains certain forward-looking statements, including, without limitation, statements containing the words "will", "may", "expects", "intends", "anticipates" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. The forward-looking statements in this news release include without limitation, statements with respect to the Private Placement and the use of proceeds of the Private Placement. These forward-looking statements involve risks and uncertainties including, but not limited to risks related to the failure to obtain necessary regulatory and stock exchange approvals, general economic and market segment conditions, and international risk and currency exchange risks, agreements and future agreements to sell our products, the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business, the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits, the acceleration of our revenue ramp, general economic and market segment conditions, competitor activity, technology changes and regulatory approvals. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's ongoing filings with the securities regulatory authorities, which filings can be found at http://www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable laws.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Read More

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Originally posted here:
SQI Diagnostics to Exhibit at the National Biotechnology Conference - Yahoo Finance

379,289 Shares in Puma Biotechnology Inc (PBYI) Acquired by … – The Cerbat Gem

Posted on by

USA Commerce Daily
379,289 Shares in Puma Biotechnology Inc (PBYI) Acquired by ...
The Cerbat Gem
Emerald Advisers Inc. PA bought a new stake in shares of Puma Biotechnology Inc (NYSE:PBYI) during the first quarter, according to its most recent Form 13F ...
Credit Suisse Group AG Reaffirms "Outperform" Rating for Puma Biotechnology Inc (PBYI)Transcript Daily
Should You Buy, Sell, Or Hold? - Puma Biotechnology, Inc. (PBYI), SkyWest, Inc. (SKYW)USA Commerce Daily
Emerald Mutual Fund Advisers Trust Takes Position in Puma ...BBNS
Chaffey Breeze -HugoPress -W News
all 17 news articles »

See the original post:
379,289 Shares in Puma Biotechnology Inc (PBYI) Acquired by ... - The Cerbat Gem

Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution … – StockNewsUnion

Posted on by

The Newburgh Press
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution ...
StockNewsUnion
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) continues to power high in the market on the back of a recently announced product distribution deal. A deal with Xenetic Biosciences is expected to make the company's products available on the ...
Traders are Following Technical Levels for Prana Biotechnology Ltd (PRAN)Rives Journal
Does Prana Biotechnology Limited (PRAN)'s current closing price competes the market?TopChronicle
Notable Institutional Stake In These Stocks: Prana Biotechnology (NASDAQ:PRAN), Adamis Pharmaceuticals ...Wallstreet Investorplace
WsNews 4investors -TRA -The Newburgh Press
all 13 news articles »

Read more:
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Soars On Xenetic Biosciences Inc. (NASDAQ:XBIO) Distribution ... - StockNewsUnion

Europe’s biotechnology potential hindered by investment fears – EurActiv

Posted on by

In terms of pure biotechnology, Europe has embraced innovation. However, it cannot compete with the US yet because it cannot drive private investment in the field, as well as open up the market to new products, a pharmaceutical executive told EURACTIV.com in Lyon.

Despite the EUs consistent growth in the biotech business, the EBE claims that the industry is not receiving enough support from investors, universities or research institutions, thus limiting the EUs ability to keep pace with the US in biotechnology.

The EU is lagging behind due to challenges in translating scientific innovations into successful businesses, a European Biopharmaceutical Enterprises (EBE) report claims.

Biotechnology is the use of living systems or organisms in the creation of industrial products. The growth of the biotechnology industry is important for Europe and created 10,000 new jobs and 93 medicines recommended for market authorisation by the European Medical Agency in 2015, according to the EBE.

Biotechnology could help patients across Europe gain access to innovative therapies, for example, against rare diseases. Proponents of bio-medicines also claim that precision therapy, because it is more efficient, will ease the burden on member states ailing healthcare systems.

The EBE suggests that steps should be taken to create a stronger investor community for biotech products to prevent places other than Europe from benefitting economically from technology invented and developed in Europe.

License to fail

The paper suggests that European entrepreneurs may be more adverse to risk because they have no license to fail, citing the lack of a strong culture of institutions or individuals seeking useful application of their work, taking out patents and creating start-up companies.

On the other hand, universities in the US often empower scientists to be knowledgeable in business and management.

The paper recommends that European institutions improve their support of scientists in marketing their technologies through better investment in Technical Transfer Offices (TTOs). The current lack of funding for TTOs at European universities means it is difficult for them to attract and train experienced staff.

Although Europe has public research funding organisations, such as the Innovative Medicines Initiative (IMI) and the European Commissions Horizon 2020, the lack of mature biotech companies makes the investment ecosystem fragile and makes it difficult for Europe to compete with the US for funding, the paper says.

Europe needs to build a bigger and better capital market for biotech companies to overcome the funding gap that prevents the needed growth of the biotech sector, it reads. The EBE suggests the European Commission create a single capital market for biotech companies and the creation of tax incentives for investment in biotechnology.

Being successful in the US

Didier Hoch, chairman of the Biovision 2017- The World Life Sciences Forum in Lyon, told EURACTIV that there are several reasons why biotechnology can flourish more easily in the US than in Europe.

According to Hoch, in terms of pure biotechnology, Europe is not lagging behind the US, as its sufficiently innovative. Where we are lagging behind is to drive investment in the field and attract private investors and open up the market to new products, he noted.

In fact, in the US the norm is to have a connection between the science, universities and private investors [] which is not yet the case in Europe, where there is a kind of fear when you are in the public sector to go private said Hoch, adding that another hindrance is the lack of trust between the public and private sector

Another difference between Washington and Brussels is the source of money. Hoch explained that money invested in the US biotech sector was coming from private investors, while in Europe, it comes from venture capital funds mainly funded by the EU institutions.

Even venture capitals are funded from EU money. This regime could eventually be thestrength for Europe, as in a way it can be competitive against private US money, he emphasised.

However, Hoch insisted that Europe still needed to convince more private sector entities to invest in biotechnology. It might be a long-term and risky field, but in the US the private sector invests in its potential, he said.

Hoch stressed that currently a biotech product could be considered successful if it has accessed the US market.

If you have a biotech company you should have in mind first to succeed in the US, even if you are based in Europe, he explained, explaining that in terms of the market, 70% of a new products success is in the US.

If you dont get your product there you will face difficulties, he said, emphasising that its mainly a political decision to have the US as an attracting market.

Last but not least, Hoch pointed out that its easier to get to the US market because there is a clear way to access and not like 27 different in the Europe, which have a country-based approach.

Making Europe innovative

In February, the centre-right European Peoples Party (EPP) presented its vision for the future of the Economic and Monetary Union (EMU) and emphasised the need for anew framework on access to financing in order for innovative companies to be encouraged to invest in Europe.

EPP President Joseph Daul told EURACTIV that the EU should become an innovation hub as this is the key to future growth and help it compete with the US.

This is where we need to concentrate our efforts to make Europe the worlds best talent hub. We should embrace radical innovations and make our continent the birthplace of the next Facebook or Apple, he told EURACTIV.

The EPP recognises that Europe was lagging behind compared to the US regarding innovative companies and, therefore, suggested the creation of an environment that will help new talents flourish.

We must understand that this follows partly from structural factors in our continent compared to our partners on the other side of the Atlantic. Venture Capital Funds in the EU are on average small. We need to support creating Funds of Funds, and we must look into existing regulations to make sure that investing in private equity funds is not discouraged by regulations and capital rules, the paper reads.

*Hannah Black contributed to this article.

See the article here:
Europe's biotechnology potential hindered by investment fears - EurActiv

Earnings Preview: Biotechnology Looks Healthy – Barron’s

Posted on by

Barron's
Earnings Preview: Biotechnology Looks Healthy
Barron's
The iShares Nasdaq Biotechnology (IBB) has climbed 0.34%. Meanwhile the SPDR S&P Biotech ETF (XBI) has declined 0.21%. IBB could be benefiting from having a wider swath of companies, in addition to the fact that the average market cap of its index ...

and more »

The rest is here:
Earnings Preview: Biotechnology Looks Healthy - Barron's

Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of … – The Cerbat Gem

Posted on by

Post Analyst
Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of ...
The Cerbat Gem
Puma Biotechnology logo Equities analysts expect that Puma Biotechnology Inc (NYSE:PBYI) will announce earnings per share (EPS) of ($2.08) for the current ...
Stock Jumping Abnormally High: Puma Biotechnology, Inc. (PBYI)HugoPress
Focusing the Lens on Puma Biotechnology, Inc. (NASDAQ:PBYI ...Rives Journal
Brokerage Firm Analysts Consensus on Puma Biotechnology, Inc. (NYSE:PBYI) SharpSpring, Inc. (NASDAQ:SHSP)Midway Monitor
Concord Register -Post Analyst -The USA Commerce
all 8 news articles »

Continue reading here:
Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of ... - The Cerbat Gem

$24 Billion Separation Systems for Commercial Biotechnology Market 2016-2021 – GlobeNewswire (press release)

Posted on by

April 05, 2017 10:57 ET | Source: Research and Markets

Dublin, April 05, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Separation Systems for Commercial Biotechnology" report to their offering.

The market for bioseparation systems is growing rapidly across all regions. Bioseparation purifies biological products on a large-scale. The report focuses on the global market of bioseparation systems and provides an updated review, including basic design and its applications, in various arenas of biomedical and life science research.

The bioseparation techniques that are covered in this report are chromatography, centrifugation, electrophoresis, membrane filtration, flow cytometry, microarray, lab-on-a-chip, biochip, and magnetic separation. Among chromatography techniques, liquid chromatography is the most active market.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the bioseparation systems market. Key players include Thermo Fisher Scientific, Agilent Technologies Inc., Bio-Rad Laboratories, Danaher Corp., Qiagen N.V., Merck KGaA GmbH, and Waters Corp. among others.

Key Topics Covered:

1: Introduction

2: Summary and highlights

3: Overview

- History of biotechnology - Classification of biomolecular separation systems in biotechnology - New methods of biomolecular separations - Molecular classes of biomolecular separation - End users of biotechnology separation systems

4: New Developments

- Mergers and acquisitions

5: Market Analysis

- Market by type - Market by region

6: Industry Structure

- Chromatography - Centrifugation - Electrophoresis - Membrane filtration - Flow cytometry - Magnetic separation - Microarrays - Biochip - Lab-on-a-chip

7: Patent Analysis

- Patents by year - Patents by type - Patents by company - Patents by country - Patents by assignee

8: Current Situation

- Factors affecting bioseparation system market - Market opportunities

9: Company Profiles

- 3M Company - Abaxis Inc. - Abtech Scientific Inc. - Agilent Technologies Inc. - Alfa Laval Group - Alfa Wassermann Separation Technologies - Arrayit Corp. - BD BioSciences (Becton, Dickinson and Company) - Biocept Inc. - Biodot Inc. - BioMerieux SA - Bio-Rad Laboratories Inc. - Boston Microfluidics - Customarray Inc. - Danaher Corp. - DNAmicroarray Inc. - Falcon Genomics Inc. - Flottweg Separation Technology - GE Healthcare Life Sciences - Hitachi Koki Co. Ltd. - Illumina Inc. - Luminex Corp. - Merck KGaA - Microarray Inc. - Nanostring Technologies Inc. - Novasep Inc. - PerkinElmer - Qiagen Gmbh - Randox Laboratories Ltd. - Sartorius Corp. - Shimadzu Scientific Instruments - Spectrum Chemical Manufacturing Corp. - Sysmex Partec Gmbh - Thermo Fisher Scientific - W. R. Grace & Company

For more information about this report visit http://www.researchandmarkets.com/research/jvlcgw/separation

Related Articles

Research and Markets Logo

LOGO URL | Copy the link below

Formats available:

Read the original post:
$24 Billion Separation Systems for Commercial Biotechnology Market 2016-2021 - GlobeNewswire (press release)

UF biotechnology institute named Incubator of the Year – The Independent Florida Alligator

Posted on by

The UF business incubator Sid Martin Biotechnology Institute was named the 2017 Top Global Incubator of the Year.

The International Business Innovation Association recognized the institute March 28, said Mark Long, the institutes director. The institute received $1,500 for winning the award out of 30 other incubators.

The biotechnology institute provides lab space, equipment, business and legal advice at a low cost for new biotech companies, Long said.

Scientists need help understanding business and addressing the market, he said. Were here to help them out with that.

The institutes 40,000 square foot facility is at Progress Park in Alachua. Its used as office and laboratory space thats rented out to new companies unable to afford commercial space.

Getting an award like this is a real marketing tool in attracting new companies and investors for these companies, Long said.

He said since the institute started in 1995, businesses theyve served have a 78 percent success rate, meaning 78 percent of businesses stay open after the first five years. Since 2003, the success rate has improved to 93 percent.

Meekah Chaderton, a manager at the startup food development company Captozyme, said the institute helped improve the companys business.

Chaderton said Captozyme plans to move out of the institute and into their own space in June.

Small companies cant afford to buy a lot of equipment and lab space, so renting affordable space from Sid Martin has made us more competitive, Chaderton said.

Follow this link:
UF biotechnology institute named Incubator of the Year - The Independent Florida Alligator

Biotechnology in Iran – Press TV

Posted on by

Iran has made a considerable breakthrough in biotechnology inasmuch as it is able to produce GM foods and Up until 2013 it has produced 18 different kinds of recombinant medicines.

The modern biotechnology has been established nearly nine decades ago in Iran, started with vaccine production in Pasteur and Razi Institutes in 1920 and 1925. National Institute of Genetic Engineering and Biotechnology institute of Iran was established in 1989. Iranian scientists are active in various spheres of agriculture in this institute and work on medicinal plants with the aim of using their metabolites or increasing their tolerance to non-biological changes such as salinity or drought. One of the uses of biotechnology is in production of genetically modified foods; however, there are many opposing voices claiming that they are harmful for health.

Simply said, biotechnology harnesses cellular and bi molecular processes and puts them to work for us. It is used for production of GM foods and treating diseases with genetic technologies and many other fields. Biotechnology is an efficient, up-to-date and effective tool in agricultural field. Biotechnology helps you to improve plants' resistance to a considerable amount. Iran is among pioneering countries in this field. Up until 2013, 18 different kinds of recombinant drugs have been produced in Iran. This number is against 50 recombinant drugs produced globally. With the help of biotechnology and recombinant drugs, Iran has seen a 30% drop in its drug export and 50% inflation growth has been controlled.

Link:
Biotechnology in Iran - Press TV

Worldwide Wound Care Market Summary 2017-2024 – Focus on Biotechnology: Advanced Biodressings, Negative Pressure Wound Systems, and More -…

Posted on by

Dublin, March 05, 2020 (GLOBE NEWSWIRE) -- The "Worldwide Wound Care Market Summary" report has been added to ResearchAndMarkets.com's offering.

Wound care is very much a challenge for both patients and healthcare providers.

Worldwide Wound Care Market Summary identifies a market opportunity for major sectors of this important market. A particular focus is given to biotechnology used in wound care, including advanced biodressings and negative pressure wound systems.

Advancements in biotechnology, biomaterials, and tissue engineering are expected to drive growth in the market during the report's forecast period. Growth is also being driven by the introduction of portable, single-use products in negative pressure wound therapy.

The report focuses on wound care advancements, providing a table of newly approved wound care products for 2019. The aging of the population and continued advances in biotechnology drive the wound care industry. It is the goal of new and existing product manufacturers to offer products designed to improve healing rates and prevent wound formation.

Market data in the report include:

World Market

Total Market by Segment

Market Segments by Application

Market by Application

The report also contains current market size for the total wound care products market for the following countries and regions:

Worldwide Wound Care Market Summary provides an outline of the competitive market, including the following data points:

Industry participants have attempted to diversify their offerings by acquiring smaller companies with new and innovative technology. This move has created more competition among large wound care companies.

Key Topics Covered

Chapter 1: Executive Summary

Chapter 2: Total Worldwide Wound Care Market Size, Forecast, and Competitive Analysis

Chapter 3: Wound Care Advancements

Chapter 4: Top Five Company Profiles(Company Overview, Performance Review)

A-Z List of Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/eyoxce

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

More here:
Worldwide Wound Care Market Summary 2017-2024 - Focus on Biotechnology: Advanced Biodressings, Negative Pressure Wound Systems, and More -...

Agricultural Biotechnology Market Research, Recent Trends and Growth Forecast 2026 – theresearchprocess.com

Posted on by

This market study on A2P SMS Market covers the global and regional market with an in-depth breakdown of the inclusive growth prospects in the market. Also, it sheds light on the wide-ranging competitive landscape of the global A2P SMS market. The report supplementary offers a dashboard overview of leading companies with their successful marketing strategies, market contribution, recent developments in both historic and present contexts. The A2P SMS Market analysis includes the global market by value, by segments and by competitors overall advancement and strategies.

The report provides insights on the following sections:

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/4613

Global A2P SMS industry profile provides top-line qualitative and quantifiable information including: A2P SMS market share, market size. The profile also contains descriptions of the foremost players including key financial metrics and analysis of competitive pressures within the A2P SMS market. Essential resource for top-line data and analysis covering the global A2P SMS market. Includes A2P SMS market size and segmentation data, textual and graphical analysis of A2P SMS market growth trends and leading companies.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/4613

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

Some of the Highlights about Table of Content of A2P SMS Market

1 A2P SMS Market overview

2 Executive Summary

3 Market Drivers, Challenges and Trends

4 Marketing, Distributors and Customer

5 Key Players Analysis

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/4613

Read more:
Agricultural Biotechnology Market Research, Recent Trends and Growth Forecast 2026 - theresearchprocess.com

Is Gritstone Oncology Inc (GRTS) a Winner or a Loser in the Biotechnology Industry – InvestorsObserver

Posted on by

Gritstone Oncology Inc (GRTS) is near the top in its industry group according to InvestorsObserver. GRTS gets an overall rating of 41. That means it scores higher than 41 percent of stocks. Gritstone Oncology Inc gets a 35 rank in the Biotechnology industry. Biotechnology is number 60 out of 148 industries.

Click Here to get the full Stock Score Report on Gritstone Oncology Inc (GRTS) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Gritstone Oncology Inc (GRTS) stock is trading at $10.73 as of 12:21 PM on Tuesday, Jan 14, an increase of $1.84, or 20.64% from the previous closing price of $8.89. The stock has traded between $8.88 and $10.99 so far today. Volume today is elevated. So far 346,361 shares have traded compared to average volume of 211,868 shares.

To see the top 5 stocks in Biotechnology click here.

Originally posted here:
Is Gritstone Oncology Inc (GRTS) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Alderaan Biotechnology raises 18.5M in Series A from Advent France Biotechnology (AFB) and Medicxi – BioSpace

Posted on by

Paris, France, January 9, 2020 Alderaan Biotechnology, a preclinical stage company focused on monoclonal antibodies development for the treatment of cancer, announces today the successful completion of a Series A funding of 18.5M ($20.7M) from investors Advent France Biotechnology (AFB) and Medicxi. This follows a seed funding round of 1.5M ($1.7M) in 2017, led by AFB.Founded by Pr Armand Bensussan, head of the Skin Research Centre, Saint Louis Hospital, Paris, and Pr Daniel Olive, head of the Immunity and Cancer team at Institut Paoli Calmette, Marseille, Alderaan Biotechnology focusses on developing technologies to deplete regulatory T (Treg) cells in cancer and to boost Natural Killer (NK) cell cytotoxic activity in cancer, both emerging as new immunotherapy modalities.This funding round will support the finalization of preclinical development to reach Phase I clinical stage, with the companys Treg depleting CD25-specific antibodies, by 2022. In parallel, the financing will also help validate thein vivotherapeutic potential of the NK asset related to the activating NK cell receptor CD160-TM (Alderaans second program).Both Medicxi and AFB, represented by Michle Ollier and Matthieu Coutet respectively, will co-lead the new investment as board directors.I am very pleased to welcome Medicxi to the company; its capital investment signals an exciting stage for Alderaan, said Arnaud Foussat, CEO of Alderaan Biotechnology. Modulating regulatory T-cells in cancer has a great therapeutic potential in oncology it could be a game changer. Our NK asset is earlier stage, but there is already a strong and encouraging interest from the pharmaceutical industry in the field.We have been working alongside Alderaan since day one and we are thrilled to be part of this next stage of development, said Matthieu Coutet, managing partner at Advent France Biotechnology. Alderaans area of focus is drawing attention from big names in the industry and the company has a solid scientific team to support its rationale.Alderaan perfectly fits with our aim, which is to invest in start-ups that have already reached scientific maturation and proof-of-concept, said Michle Ollier, partner at Medicxi. The companys technologies are very attractive to the pharmaceutical industry and could become key additional therapeutic tools for patients and health professionals.Advisors to AlderaanLegal: Mac DermottFinancial: DeloitteAdvisors to MedixciLegal: Jones DayAbout Advent France BiotechnologyAdvent France Biotechnology is an AMF regulated firm created in 2016. The team, managed by Alain Huriez and Matthieu Coutet, includes professionals with extensive scientific, medical and operational experience, as well as a long-standing track record of entrepreneurial and investment successes across Europe. AFB invests in a range of sectors within the life sciences, specifically in drug discovery and new medical technologies.www.adventFB.comAbout MedicxiMedicxi is a European venture capital firm with the mission to create and invest in companies along the full drug development continuum. Medicxi was established by the former Index Ventures life sciences team, which has been active for over 20 years, and invests in both early and late-stage assets with a product vision that can fulfil a clear unmet need.GSK, Johnson & Johnson Innovation JJDC, Inc.,Novartis and Verily (an Alphabet company) have invested in Medicxi funds.www.medicxi.comAbout Alderaan BiotechnologyAlderaan Biotechnology is a preclinical stage company focused on monoclonal antibodies development for the treatment of cancer with technologies aiming at Treg depletion and NK cell modulation. Founded in 2017 and headquartered in Paris, Alderaan works with world-class teams in the field of immunomodulation and NK cell receptors. The company raised 1.5M ($1.7M) in 2017 from co-founder Advent France Biotechnology (AFB) and 18.5M ($20.7M) in 2019 from AFB and Medicxi.www.linkedin.com/company/alderaan-biotechnology/about/

Read the rest here:
Alderaan Biotechnology raises 18.5M in Series A from Advent France Biotechnology (AFB) and Medicxi - BioSpace